NCT04762589View on ClinicalTrials.gov

RT001 in Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

June 28, 2022

Study Completion Date

June 28, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

RT001

RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months

DRUG

Placebo

Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.

Trial Locations (4)

Unknown

University of Tartu, Tartu

Riga Stradins Universtiy, Riga

UMC Utrecht, Utrecht

Karolinska, Stockholm

All Listed Sponsors
lead

Biojiva LLC

INDUSTRY

NCT04762589 - RT001 in Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter